Search by Drug Name or NDC
NDC 25021-0254-08 Docetaxel 10 mg/mL Details
Docetaxel 10 mg/mL
Docetaxel is a INTRAVENOUS INJECTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Sagent Pharmaceuticals. The primary component is DOCETAXEL ANHYDROUS.
MedlinePlus Drug Summary
Docetaxel injection is used alone or in combination with other medications to treat certain types of breast, lung, prostate, stomach, and head and neck cancers. Docetaxel injection is in a class of medications called taxanes. It works by stopping the growth and spread of cancer cells.
Related Packages: 25021-0254-08Last Updated: 03/24/2024
MedLinePlus Full Drug Details: Docetaxel Injection
Product Information
| NDC | 25021-0254 |
|---|---|
| Product ID | 25021-254_841e3024-e160-4c4b-93d3-1e79d628d95b |
| Associated GPIs | |
| GCN Sequence Number | 067167 |
| GCN Sequence Number Description | docetaxel VIAL 80 MG/8 ML INTRAVEN |
| HIC3 | V1F |
| HIC3 Description | ANTINEOPLASTICS,MISCELLANEOUS |
| GCN | 29662 |
| HICL Sequence Number | 010280 |
| HICL Sequence Number Description | DOCETAXEL |
| Brand/Generic | Generic |
| Proprietary Name | Docetaxel |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | Docetaxel Anhydrous |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | INJECTION |
| Route | INTRAVENOUS |
| Active Ingredient Strength | 10 |
| Active Ingredient Units | mg/mL |
| Substance Name | DOCETAXEL ANHYDROUS |
| Labeler Name | Sagent Pharmaceuticals |
| Pharmaceutical Class | Microtubule Inhibition [PE], Microtubule Inhibitor [EPC] |
| DEA Schedule | n/a |
| Marketing Category | ANDA |
| Application Number | ANDA213510 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 25021-0254-08 (25021025408)
| NDC Package Code | 25021-254-08 |
|---|---|
| Billing NDC | 25021025408 |
| Package | 1 VIAL in 1 CARTON (25021-254-08) / 8 mL in 1 VIAL |
| Marketing Start Date | 2023-08-01 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |